Price
No data yet.
Social Signal Score
Revenue
$23.2K+43.42%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Katharyn Field
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 14
- Beta
- 0.74
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -57.22
Financials
Revenue
$23.2K+43.4%Net Income
$-2.15MEBITDA
$-2.10MFree Cash Flow
$-3.81MEPS (diluted)
$-0.24Shares Outstanding (diluted)
8.99M+867961.3%Operating Expenses
$3.40MCash & Debt
$3.59MReturn of Capital
$6.1KRevenue by Segment (annual)
$359.7KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $359.7K | $-14.24M | $-1.58 |
| 2024 | $401.0K | $-8.98M | $-1.16 |
| 2023 | $145.8K | $-10.42M | $-2.47 |
| 2022 | $119.8K | $-13.22M | $-3.65 |
| 2021 | $46.0K | $-44.30M | $-37.30 |
| 2020 | $77.0K | $-11.27M | $-28.56 |
| 2019 | $130.0K | $-14.65M | $-3217.82 |
| 2018 | $111.0K | $-12.52M | $-4269.37 |
| 2017 | $81.0K | $-9.44M | $-6181.06 |
| 2016 | $36.4K | $-8.64M | $-7356.30 |
| 2015 | $628.9K | $-7.92M | $-9580.99 |
| 2014 | $416.0K | $-5.59M | $-13178.33 |
| 2013 | $1.7K | $-5.75M | $-24164.68 |
| 2012 | $15.6K | $-6.54M | $-35143.67 |
Valuation
BRTXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
120Social Signal Score
Mentions (1)
- Newsglobenewswire.com·6h ago·Positive
BioRestorative Therapies Announces Reverse Stock Split MELVILLE, N.Y., Sept. 02, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (Nasdaq: BRTX) (“BioRestorative” or the “Company”), a late-stage clinical regenerative medicine company, today announced that the Company's Board of Directors approved a 1-for-20 reverse stock split (the “Reverse Stock Split”) of the Company's common stock (the “Common Stock”). The Company was not required to obtain stockholder approval to effectuate the Revers…
View source ↗
Earnings
Tue, Sep 8(in 5 days)
Consensus estimate $-0.10 per share
Typical surprise +17.1% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, May 14$-0.19 vs $-0.30beat
- Thu, Mar 26$-0.37 vs $-0.37beat
- Wed, Nov 12$-0.33 vs $-0.36beat
- Tue, Aug 12$-0.30 vs $-0.41beat
- Wed, May 14$-0.56 vs $-0.32miss
- Thu, Mar 27$-0.20 vs $-0.27beat
Estimates and results for BRTX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by BRTX officers and directors.
- Bought
- $515k
- Sold
- $16k
46 trades
4 trades
- Broadrick Dalesold
- Silva Franciscobought
- Silva Franciscobought
- Silva Franciscobought
- Broadrick Dalebought
- Broadrick Dalebought
- Broadrick Dalebought
- Broadrick Dalebought
50 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.